Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
British Journal of Cancer|April 23, 2005
Lack of clinical efficacy of imatinib in metastatic melanomaS Ugurel, R Hildenbrand, A Zimpfer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 29, 2006
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO studyD Schadendorf, A Hauschild, S Ugurel, et al.The Journal of Pathology|February 17, 2006
Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesisK Schledzewski, M Falkowski, G Moldenhauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology GroupU Reinhold, C Berkin, A K Bosserhoff, et al.British Journal of Cancer|April 20, 2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)A Hauschild, C Garbe, W Stolz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 2, 2021
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitorsP Jansen, G C Lodde, A Wetter, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaS Ugurel, D Schadendorf, K Horny, et al.Cancer Immunology, Immunotherapy : CII|April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG studyH M Stege, M Haist, S Schultheis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.Pageof 6